Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Year’s Congress Likely To Reinforce ACA Preexisting Conditions, Attorneys Say

Supreme Court action on ACA constitutional case not expected until June, so Democrats plan to shore up the act’s provisions through lawmaking in interim

Executive Summary

Industry attorneys predict that in the absence of the Supreme Court’s immediate response to arguments made in a key Affordable Care Act constitutionality case, that Congress will reaffirm the law.

You may also be interested in...



Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic

Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.

US Election 2020: Industry Loses Three Favored Incumbents In Battle For Senate Control

A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election.

Seating Of Barrett On Supreme Court Could Be Death Knell For ACA’s Chronic Illness Coverage

During her confirmation hearings, Judge Amy Coney Barrett denied it’s her goal to end all Affordable Care Act coverage, but some senators and legal experts disagree. And if the ACA is struck down, coverage for chronic disease treated with medical devices – including cancer, heart disease and diabetes – could fall by the wayside.

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel